Abu Dhabi-headquartered Arcera Life Sciences and Shanghai-based biopharmaceutical firm Innogen Pharmaceuticals (HKEX: 2591) announced an exclusive licensing and commercialization agreement for Efsubaglutide Alfa, a GLP-1 receptor agonist therapy.
Under the terms of the agreement, Arcera secures exclusive rights to develop and commercialize the cardiometabolic therapy across agreed territories, including the United Arab Emirates and selected countries in the Middle East, Africa, Eastern Europe, and Latin America. Innogen retains rights in the rest of the world.
Innogen will receive US$38 million in upfront and near-term milestone payments, which includes a non-refundable upfront payment of US$15 million. In addition, Innogen is eligible to receive sales milestone payments and tiered royalties of up to a double-digit percentage based on aggregate annual net sales in the licensed territories. The total potential value of the transaction exceeds US$1 billion.
The companies stated that Arcera will manage regulatory activities, market access, and commercialization within the covered territories. The transaction marks a milestone in expanding international distribution for an innovative GLP-1 therapy developed in China.
Sources
- Macau Business · 2026-11-19



